Newsletter December 2024
EPO End of Year Summary
Dear Colleagues,
As the year draws to a close, we extend our warmest holiday greetings and heartfelt thanks for trusting us to partner with you in accelerating your preclinical oncology drug development programs. This year has been a remarkable journey in advancements in preclinical oncology research. We've supported advancements across a spectrum of tumor types, treatment modalities, and in vivo / in vitro disease models.
We are also proud to announce the establishment of EPO-Oncodiscovery, our new U.S.-based site. This expansion strengthens our ability to connect with clients and partners across North America, attend key oncology conferences, and provide localized expertise in preclinical oncology drug development.
Key Highlights from our Newsletters in 2024:
Kicking off the year strong with EPO’s published work in Cancers on 45 pancreatic carcinoma PDX models, highlighting their value in preclinical drug testing and personalized therapy development.
Read More
February 2024: Advancing T-Cell Therapies through Collaboration
EPO Berlin-Buch secures funding from the ProFIT program and the EU (EFRE) to support a collaborative project on TCR-T therapies targeting pancreatic, colorectal, and breast cancers driving development of innovative and personalized therapies.
March 2024: EPO Highlighted at AACR
At AACR in San Diego, EPO hosted a lively reception and presented groundbreaking research on immune oncology and predictive tumor models, connecting with colleagues and showcasing our latest scientific advancements.
May 2024: Advancing Glioblastoma Research
At the Brain Tumor Meeting in Berlin, EPO presented updates on our glioblastoma (GBM) research, showcasing our comprehensive PDX models and new glioma cell lines, while discussing their potential for accelerating drug development.
June 2024: EPO's Role in Advancing Pediatric Cancer Research
Through EPO’s collaboration with ITCC-P4, we continue to drive pediatric cancer research by providing access to over 400 well-characterized patient-derived pediatric PDX models
July 2024: Tumor Models Boston Summit
Showcasing EPO’s latest advancements in translational oncology models, focusing on de-risking target validation, predicting therapeutic responses, and supporting biomarker discovery
August 2024: EPO Advances Breast Cancer Research
EPO makes continued strides in breast cancer research with our robust PDX portfolio, including 15 models for Triple-Negative Breast Cancer (TNBC) and the development of Invasive Lobular Carcinoma (ILC) models.
September 2024: Advancing Tumor Resistance Models at EPO
EPO continues to advance tumor resistance models, integrating chemosensitivity data and genomic insights to elucidate mechanisms of drug resistance and empower development of new more effective therapies.
November 2024: ADC Advancements and Innovations at EPO
EPO is advancing research and showing promising efficacy in Antibody-Drug Conjugates (ADCs) and Small Molecule-Drug Conjugates (SMDCs) for Triple-Negative Breast Cancer (TNBC) and other hard-to-treat cancers.
Thank you for your continued partnership and support. We look forward to driving more advancements together in the coming year.
For inquiries, please contact Turn on Javascript! or Turn on Javascript!, or reach out directly to our business development representatives, Turn on Javascript! (EPO-USA) and Turn on Javascript! (EPO-Berlin), to discuss how we can accelerate your drug development program.
Best regards,
Jens Hoffmann & Wolfgang Walther
CEO & CSO at EPO Berlin-Buch